Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Apr;36(4):744–750. doi: 10.1128/aac.36.4.744

Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis.

G Potel 1, J Caillon 1, F Le Gallou 1, D Bugnon 1, P Le Conte 1, J Raza 1, J Y Lepage 1, D Baron 1, H Drugeon 1
PMCID: PMC189385  PMID: 1503436

Abstract

Aminoglycoside bactericidal activity during the first 24 h of treatment probably is a determining parameter in the prognosis of severe gram-negative infections in immunocompromised patients. To identify the predictive factors involved in the definition of the best therapeutic regimen for Enterobacter cloacae and Serratia marcescens infections, we studied different gentamicin, tobramycin, and amikacin regimens by using an experimental model of rabbit endocarditis. Two factors appear to play an important role in predicting in vivo efficacy: (i) the level of in vivo bactericidal activity, which can differ widely from one aminoglycoside to another for the same bacterial strain and from one strain to another of the same species, and (ii) the critical serum drug concentration (CSC, in milligrams per liter), defined as the lowest serum antibiotic concentration capable of producing a significant CFU reduction (P less than 0.05) in endocarditis vegetations 24 h after the beginning of a continuous infusion. Stepwise regression analysis showed that for gentamicin and S. marcescens, the area under the concentration-time curve above the CSC and then the time above the CSC are the determining parameters for efficacy (R = 0.69; F = 13.5; P = 0.001), whereas for amikacin and S. marcescens, the time above the CSC and then the area under the concentration-time curve above the CSC predict efficacy (R = 0.74; F = 24.0; P = 0.0001). The lowest CSC is that of amikacin (about 8 mg/liter); those of gentamicin and tobramycin are about 15 mg/liter. In severe S. marcescens infections, intermittent amikacin dosing offers excellent bactericidal activity within the first 24 h.

Full text

PDF
744

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beaucaire G., Leroy O., Beuscart C., Karp P., Chidiac C., Caillaux M. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother. 1991 May;27 (Suppl 100):91–103. doi: 10.1093/jac/27.suppl_c.91. [DOI] [PubMed] [Google Scholar]
  2. Billiau V., Beuscart C., Leroy O., Dujardin P. J., Beaucaire G., Chidiac C., Mouton Y., Ses G. Septicémies a Enterobacter, Serratia, Acinetobacter ou Pseudomonas. Pathol Biol (Paris) 1989 Jan;37(1):39–42. [PubMed] [Google Scholar]
  3. Craig W. A., Redington J., Ebert S. C. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother. 1991 May;27 (Suppl 100):29–40. doi: 10.1093/jac/27.suppl_c.29. [DOI] [PubMed] [Google Scholar]
  4. Daikos G. L., Jackson G. G., Lolans V. T., Livermore D. M. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis. 1990 Aug;162(2):414–420. doi: 10.1093/infdis/162.2.414. [DOI] [PubMed] [Google Scholar]
  5. De Broe M. E., Verbist L., Verpooten G. A. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother. 1991 May;27 (Suppl 100):41–47. doi: 10.1093/jac/27.suppl_c.41. [DOI] [PubMed] [Google Scholar]
  6. Drugeon H. B., Caillon J., Juvin M. E., Pirault J. L. Dynamics of ceftazidime-pefloxacin interaction shown by a new killing curve-chequerboard method. J Antimicrob Chemother. 1987 Feb;19(2):197–203. doi: 10.1093/jac/19.2.197. [DOI] [PubMed] [Google Scholar]
  7. Feld R., Tuffnell P. G., Curtis J. E., Messner H. A., Hasselback R. Empiric therapy for infections in granulocytopenic cancer patients: continuous infusion of amikacin plus cephalothin. Arch Intern Med. 1979 Mar;139(3):310–314. [PubMed] [Google Scholar]
  8. Garraffo R., Drugeon H. B., Dellamonica P., Bernard E., Lapalus P. Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother. 1990 Apr;34(4):614–621. doi: 10.1128/aac.34.4.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gerber A. U., Brugger H. P., Feller C., Stritzko T., Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis. 1986 Jan;153(1):90–97. doi: 10.1093/infdis/153.1.90. [DOI] [PubMed] [Google Scholar]
  10. Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jackson G. G., Lolans V. T., Daikos G. L. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis. 1990 Aug;162(2):408–413. doi: 10.1093/infdis/162.2.408. [DOI] [PubMed] [Google Scholar]
  12. Kapusnik J. E., Hackbarth C. J., Chambers H. F., Carpenter T., Sande M. A. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988 Jul;158(1):7–12. doi: 10.1093/infdis/158.1.7. [DOI] [PubMed] [Google Scholar]
  13. Keating M. J., Bodey G. P., Valdivieso M., Rodriguez V. A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine (Baltimore) 1979 Mar;58(2):159–170. doi: 10.1097/00005792-197903000-00004. [DOI] [PubMed] [Google Scholar]
  14. LeBel M., Spino M. Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet. 1988 Feb;14(2):71–95. doi: 10.2165/00003088-198814020-00002. [DOI] [PubMed] [Google Scholar]
  15. Leggett J. E., Fantin B., Ebert S., Totsuka K., Vogelman B., Calame W., Mattie H., Craig W. A. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989 Feb;159(2):281–292. doi: 10.1093/infdis/159.2.281. [DOI] [PubMed] [Google Scholar]
  16. McConkey S. J., Coleman D. C., Falkiner F. R., McCann S. R., Daly P. A. Enterobacter cloacae in a haematology/oncology ward--first impressions. J Hosp Infect. 1989 Nov;14(4):277–284. doi: 10.1016/0195-6701(89)90067-4. [DOI] [PubMed] [Google Scholar]
  17. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  18. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Perlman B. B., Freedman L. R. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med. 1971 Oct;44(2):206–213. [PMC free article] [PubMed] [Google Scholar]
  20. Potel G., Caillon J., Fantin B., Raza J., Le Gallou F., Lepage J. Y., Le Conte P., Bugnon D., Baron D., Drugeon H. Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation. Antimicrob Agents Chemother. 1991 Jan;35(1):111–116. doi: 10.1128/aac.35.1.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Potel G., Chau N. P., Pangon B., Fantin B., Vallois J. M., Faurisson F., Carbon C. Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding. Antimicrob Agents Chemother. 1991 Oct;35(10):2085–2090. doi: 10.1128/aac.35.10.2085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Powell S. H., Thompson W. L., Luthe M. A., Stern R. C., Grossniklaus D. A., Bloxham D. D., Groden D. L., Jacobs M. R., DiScenna A. O., Cash H. A. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis. 1983 May;147(5):918–932. doi: 10.1093/infdis/147.5.918. [DOI] [PubMed] [Google Scholar]
  23. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W. A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988 Oct;158(4):831–847. doi: 10.1093/infdis/158.4.831. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES